PharmaSeq

Home Company News & Events Press Releases 2008 Government Contract to Develop Advanced Assay to Detect Prostate Cancer

Press Releases

Government Contract to Develop Advanced Assay to Detect Prostate Cancer

Monmouth Junction, NJ, September 22, 2008. PharmaSeq, Inc., announced today the receipt of the Phase I SBIR contract from National Cancer Institute of the NIH to develop an advanced in vitro assay to detect prostate cancer. The assay will be based on the proprietary PharmaSeq microtransponder system.

The main goal of the grant is to develop an improved, multiplex diagnostic that will simultaneously measure three biomarkers for early prostate cancer detection. Current diagnostics use a single biomarker. The test will use PharmaSeq's light-powered microtransponders, which are miniature RFID devices. The immunoassay is based on using three antibodies conjugated to the microtransponders, which are then hybridized to a targeted antigen specimen, followed by detection.

Dr. Wlodek Mandecki, President of PharmaSeq, Inc., said: "Simultaneous determination of three biomarkers in a small, limited clinical sample volume will benefit the cost-effective early diagnosis and treatment of prostate cancer before it progresses to metastasis. The work will establish a new, more reliable protein immunoassay on our innovative platform."

For further information, please contact Dr. Richard Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

Home Company News & Events Press Releases 2008 Government Contract to Develop Advanced Assay to Detect Prostate Cancer